Hierarchical modeling of patient and physician determinants of blood pressure outcomes in adherent vs nonadherent hypertensive patients: Pooled analysis of 6 studies with 14,646 evaluable patients

Journal of Clinical Hypertension

Volumn 15, Issue 9, 2013, Pages 663-673

  Abraham, Ivo ^a,b,c   Van Camp, Yoleen ^a,c,d   Villa, Lorenzo ^a,c,e   Denhaerynck, Kris ^c,f   Sun, Diana ^a,c   Vancayzeele, Stefaan ^g   Brié, Heidi ^g   Aerts, Ann ^h   Hermans, Christine ^g   Macdonald, Karen ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c Matrix45   (United States)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e UNIVERSITY OF CONCEPCIÓN   (Chile)

^f UNIVERSITY OF BASEL   (Switzerland)

^g Novartis Pharma   (Belgium)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; AMLODIPINE PLUS VALSARTAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; VALSARTAN;

ADULT; ALERTNESS; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHYSICIAN; PREDICTIVE VALUE; PRESCRIPTION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COHORT STUDIES; FEMALE; HUMANS; HYPERTENSION; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIAN-PATIENT RELATIONS; SELF REPORT; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 84883446552     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12163     Document Type: Article

References (32)

1. DiMatteo MR. Variations in patients' adherence to medical recommendations - a quantitative review of 50 years of research. Med Care. 2004;42:200-209.
2. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. Br Med J. 2008;336:1114-1117.
3. Hill MN, Miller NH, DeGeest S, American Socociety of Hypertension Writing Group. ASH position paper: adherence and persistence with taking medication to control high blood pressure. J Clin Hypertens (Greenwich). 2010;12:757-764.
4. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes - a meta-analysis. Med Care. 2002;40:794-811.
5. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120:1598-1605.
6. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:1957-1963.
7. Fagard RH, Van den Enden M, Leeman M, Warling X. Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium. J Hypertens. 2002;20:1297-1302.
8. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206.
9. Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum - current outcomes and control in the community. JAMA. 2005;294:466-472.
10. Van der Niepen P, Giot C, van de Borne P. Prevalence of isolated uncontrolled systolic blood pressure among treated hypertensive patients in primary care in Belgium: results of the I-inSYST survey. J Hypertens. 2008;26:1057-2063.
11. Rose AJ, Glickman ME, D'Amore MM, et al. Effects of daily adherence to antihypertensive medication on blood pressure control. J Clin Hypertens (Greenwich). 2011;13:416-421.
12. Shelley D, Tseng TY, Andrews H, et al. Predictors of blood pressure control among hypertensives in community health centers. Am J Hypertens. 2011;24:1318-1323.
13. Morris AB, Li JJ, Kroenke K, et al. Factors associated with drug adherence and blood pressure control in patients with hypertension. Pharmacotherapy. 2006;26:483-492.
14. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. World Health Organization: Geneva, Switzerland; 2003.
15. Abraham I, MacDonald K, Hermans C, et al. Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program. Vasc Health Risk Manag. 2011;7:209-235.
16. Villa L, Abraham I, Macdonald K, Denhaerynck K. Correlation of physician-rated adherence with therapeutical outcomes in antihypertensive treatment: pooled analysis findings from six valsartan studies including 15, 583 available patients. Value Health. 2011;14:A383-A384.
17. Dobbels F, Berben L, De Simone S, et al. The psychometric properties and practicability of self-report instruments to identify medication non-adherence in adult transplant patients: a systematic review. Transplantation. 2010;90:205-219.
18. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67-74.
19. Twisk JWR. Applied Multilevel Analysis. Cambridge: University Press; 2006.
20. Kreft I, De Leeuw J. Introducing Multilevel Modeling. Thousand Oaks, CA: Sage; 2002.
21. Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;Art. No.: CD000011.
22. Planas LG, Crosby KM, Mitchell KD, Farmer KC. Evaluation of a hypertension medication therapy management program in patients with diabetes. J Am Pharm Assoc. 2009;49:164-170.
23. Gutierrez-Angulo ML, Lopetegi-Uranga P, Sanchez-Martin I, Garaigordobil-Landazabal M. [Therapeutic compliance in patients with arterial hypertension and type 2 diabetes mellitus]. Rev Calid Asist. 2012;27:72-77.
24. Stults B, Jones R. Management of hypertension in diabetes. Diabetes Spectr. 2006;19:25-31.
25. Verpooten GA, Aerts A, Coen N, et al. Antihypertensive effectiveness of aliskiren for the 'real-world' management of hypertension: multilevel modelling of 180-day blood pressure outcomes (the Belgian DRIVER Study). Int J Clin Pract. 2011;65:54-63.
26. Choudhry NK, Fletcher RH, Soumerai SB. Systematic review: the relationship between clinical experience and quality of health care. Ann Intern Med. 2005;142:260-273.
27. Gouni-Berthold I, Berthold HK. Role of physician gender in drug therapy. Handb Exp Pharmacol. 2012;214:183-208.
28. Scheen AJ, Philips JC, Krzesinski JM. [Hypertension and diabetes: about a common but complex association]. Rev Med Liege. 2012;67:133-138.
29. Ruckert IM, Schunk M, Holle R, et al. Blood pressure and lipid management fall far short in persons with type 2 diabetes: results from the DIAB-CORE Consortium including six German population-based studies. Cardiovasc Diabetol. 2012;11:50.
30. Sakurai M, Stamler J, Miura K, et al. Relationship of dietary cholesterol to blood pressure: the INTERMAP study. J Hypertens. 2011;29:222-228.
31. de Simone G, Devereux RB, Chinali M, et al. Risk factors for arterial hypertension in adults with initial optimal blood pressure - the strong heart study. Hypertension. 2006;47:162-167.
32. Frampton JE, Scott LJ. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension. Am J Cardiovasc Drugs. 2009;9:309-330.